v3.26.3
Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2026
Fair Value Disclosures [Abstract]  
Schedule of Financial Instruments Measured at Fair Value
A summary of financial instruments measured at fair value was as follows (in thousands):
September 30, 2026Level 1Level 2Level 3Total
Cash equivalents
Money market funds$10,668 $— $— $10,668 
Certificates of deposit1,132 — — 1,132 
Total assets$11,800 $— $— $11,800 
Liabilities
Current portion of contingent consideration$— $— $— $— 
Non-current contingent consideration— — 71,100 71,100 
Total liabilities$— $— $71,100 $71,100 
December 31, 2025Level 1Level 2Level 3Total
Cash equivalents
Money market funds$20,725 $— $— $20,725 
Certificates of deposit1,080 — — 1,080 
Endospan Loans— — 19,872 19,872 
Total assets$21,805 $— $19,872 $41,677 
Liabilities
Current portion of contingent consideration$— $— $20,690 $20,690 
Non-current contingent consideration— — 39,890 39,890 
Total liabilities$— $— $60,580 $60,580 
Schedule of Reconciliation of Changes in Fair Value of Level 3 Liabilities Changes in fair value of Level 3 assets and liabilities are listed in the tables below (in thousands):
AMDS Contingent Consideration
Balance as of December 31, 2025$60,580 
PMA approval payment(25,000)
Change in valuation 10,840 
Balance as of September 30, 2026$46,420 
Endospan Contingent Consideration
Balance as of December 31, 2025$— 
Initial value21,782 
Change in valuation2,898 
Balance as of September 30, 2026$24,680